



Electronic Health Record (EHR)

Instructions to Create a Protocol for Atopic Dermatitis (AD) with NEMLUVIO® in the EMA® EHR System

IMPORTANT SAFETY INFORMATION

INDICATION: NEMLUVIO® (nemolizumab-ilto) is an interleukin-31 receptor alpha antagonist indicated for the treatment of adults and pediatric patients 12 years of age and older with moderate-to-severe atopic dermatitis in combination with topical corticosteroids and/or calcineurin inhibitors when the disease is not adequately controlled with topical prescription therapies.

CONTRAINDICATION: NEMLUVIO is contraindicated in patients with known hypersensitivity to nemolizumab-ilto or to any of the excipients in NEMLUVIO.

Please see Important Safety Information on page 8 and accompanying Prescribing Information or click here for full [Prescribing Information](#) including Patient Information.

EMA, Electronic Medical Assistant.

Background, Instructions, and Limitations

Indication

NEMLUVIO is indicated for the treatment of patients aged 12 years and older with moderate-to-severe atopic dermatitis in combination with topical corticosteroids and/or calcineurin inhibitors when the disease is not adequately controlled with topical prescription therapies.¹

Limitations of Use

These instructions were created specifically to update a protocol in the EMA EHR system and will not work in other EHR systems. These instructions are designed to be used for NEMLUVIO for the treatment of AD and should not be used for other conditions, treatments, or therapeutic areas.

The processes outlined in this piece are variable and not all steps will apply to every health system. Any steps or settings that are not part of a health system's standard process should be excluded or modified accordingly. Any questions should be directed to the appropriate service provider. The practice is solely responsible for implementing, testing, monitoring, and ongoing operation of any EHR tools.

A health system may choose to optimize existing EHR protocols or to create a new protocol for NEMLUVIO. Protocols consolidate notes, referrals, imaging studies, lab orders and bundles, medications, patient education, coding and billing information, and other orderable items used to manage a condition or problem. Protocols can improve the user experience and help reduce practice variation. These instructions detail specifically how to add the initiation and maintenance dosing of NEMLUVIO to protocols.

AD, atopic dermatitis; EHR, electronic health record; EMA, Electronic Medical Assistant.

Please see Important Safety Information on page 8 and accompanying Prescribing Information or click here for full [Prescribing Information](#) including Patient Information.

Recommended Dosage of NEMLUVIO for AD¹:



- Concomitant topical therapies:

- Use NEMLUVIO with topical corticosteroids and/or topical calcineurin inhibitors. When the disease has sufficiently improved, discontinue use of topical therapies¹

Complete all age-appropriate vaccinations as recommended by current immunization guidelines prior to initiating treatment with NEMLUVIO [see *Warnings and Precautions* (5.2)].¹

Review the NEMLUVIO Prescribing Information for additional information, including important administration instructions, preparation for use of NEMLUVIO, missed dose information, and additional information.

Mechanism of Action

- NEMLUVIO is a humanized monoclonal antibody of the IgG2 subclass that inhibits IL-31 signaling by binding selectively to IL-31RA¹
- IL-31 is a naturally occurring cytokine that is involved in pruritis, inflammation, epidermal dysregulation, and fibrosis¹
- NEMLUVIO inhibited IL-31-induced responses including the release of proinflammatory cytokines and chemokines¹

AD, atopic dermatitis; IgG, immunoglobulin G; IL-31RA, interleukin-31 receptor alpha; Q8W, every 8 weeks.

Please see Important Safety Information on page 8 and accompanying Prescribing Information or click here for full [Prescribing Information](#) including Patient Information.

EMA Instructions

EMA comes with a wide range of dermatology-specific protocols. New protocols may be created by the user and shared with other clinicians within the practice. Since NEMLUVIO has an initiation and maintenance dosing (every 4 weeks [Q4W]), consider creating 2 separate plans or protocols for NEMLUVIO if this approach is aligned with your governing EHR plan conventions and builds.

- 1 Open the web version of EMA
- 2 Click Preferences (in the top-right corner of the window) and select Manage Protocols
- 3 Search for existing protocols in the system. Click the tab to toggle between My Protocols and Practice Protocols
- 4 Click Add Protocol
- 5 Complete the Protocol information by entering a unique title, for example “NEMLUVIO initiation for atopic dermatitis” and “NEMLUVIO maintenance for atopic dermatitis”. Consider adding keywords “atopic dermatitis” to help users searching for Protocols
- 6 Under Shared with Everyone in Firm, select the Yes radio button to make the protocol available to other users in the practice
- 7 Any desired items can be added to the Protocol. Consider the Exam Set, Diagnosis, Location, etc., as desired
- 8 Click Save. The Virtual Exam Room will open to complete the Protocol

Instructions continued on the next page.

EHR, electronic health record; EMA, Electronic Medical Assistant.

Please see Important Safety Information on page 8 and accompanying Prescribing Information or click here for full [Prescribing Information](#) including Patient Information.

EMA Instructions (cont'd)

- 9 In the Plans section, select Prescription, then Find Other Medication, search for and select NEMLUVIO. Add the NEMLUVIO medication details:

For the NEMLUVIO initiation for AD plan, complete the medication details below¹:

- The recommended initiation dosage of NEMLUVIO in patients aged 12 years and older is
 - An initial dose of 60 mg (two 30 mg injections)
- **Concomitant topical therapies:**
 - Use NEMLUVIO with topical corticosteroids and/or topical calcineurin inhibitors. When the disease has sufficiently improved, discontinue use of topical therapies

For the NEMLUVIO maintenance for AD plan, complete the medication details below¹:*

- The recommended maintenance dosage of NEMLUVIO in patients aged 12 years and older is
 - A maintenance dosing of 30 mg given every 4 weeks (Q4W)
 - After 16 weeks of treatment, for patients who achieve clear or almost clear skin, a dosage of 30 mg Q4W or every 8 weeks (Q8W) is recommended
- **Concomitant topical therapies:**
 - Use NEMLUVIO with topical corticosteroids and/or topical calcineurin inhibitors. When the disease has sufficiently improved, discontinue use of topical therapies

Instructions continued on the next page.

AD, atopic dermatitis; EMA, Electronic Medical Assistant.

*Maintenance dosing starts 4 weeks after initial dose.¹

Please see Important Safety Information on page 8 and accompanying Prescribing Information or click here for full [Prescribing Information](#) including Patient Information.

EMA Instructions (cont'd)

10 In the Counseling section, consider adding:


The hyperlink to the current NEMLUVIO PI (which includes the NEMLUVIO recommended vaccinations prior to treatment initiation, dosage and administration, warnings and precautions, and adverse reactions):

https://www.galderma.com/sites/default/files/2024-12/Nemluvio_Dual%20PI%20for%20website%2013Dec24.pdf




The hyperlink and QR code accessing the NEMLUVIO enrollment form. Note: the patient enrollment form has 2 prescriptions on the bottom of the form (for quick start and regular prescription):

<https://www.nemluviohcp.com/pdf/enrollment-form.pdf>



The hyperlink to the NEMLUVIO patient savings card for Commercial patients:

<https://www.GaldermaHCP.Portal.com>



NEMLUVIO has a limited distribution network and is available at:

<https://www.nemluviohcp.com/pdf/specialty-pharmacy-facts.pdf>



- 11 Click Done at the bottom of the prescription to save the medication details
- 12 In the Follow Up section, set any follow-up appointments as desired
- 13 Click Save Visit Protocol

PI, Prescribing Information.

Please see Important Safety Information on page 8 and accompanying Prescribing Information or click here for full [Prescribing Information](#) including Patient Information.

Notes

The customers (i.e., physician, medical group, integrated delivery network) shall be solely responsible for implementation, testing, and monitoring of the instructions to ensure proper orientation in each customer's EHR system.

Capabilities, functionality, and setup (customization) for each EHR system may vary. Galderma shall not be responsible for revising the implementation instructions it provides to any customer if the customer modifies or changes its software, or the configuration of its EHR system, after such time as the implementation instructions have been initially provided by Galderma.

While Galderma tests its implementation instructions on multiple EHR systems, the instructions are not guaranteed to work for all available EHR systems and Galderma shall have no liability thereto.

While EHRs may assist providers in identifying appropriate patients for consideration of assessment, treatment, and referral, the decision and action should ultimately be decided by a provider in consultation with the patient after a review of the patient's records to determine eligibility, and Galderma shall have no liability thereto.

The instructions have not been designed to and are not tools and/or solutions for meeting Advancing Care Information and/or any other quality/accreditation requirement.

All products are trademarks of their respective holders, all rights reserved. Reference to these products is not intended to imply affiliation with or sponsorship of Galderma and/or its affiliates.

EHR, electronic health record.

Please see Important Safety Information on page 8 and accompanying Prescribing Information or click here for full [Prescribing Information](#) including Patient Information.

Important Safety Information

INDICATION: NEMLUVIO® (nemolizumab-ilto) is an interleukin-31 receptor alpha antagonist indicated for the treatment of adults and pediatric patients 12 years of age and older with moderate-to-severe atopic dermatitis in combination with topical corticosteroids and/or calcineurin inhibitors when the disease is not adequately controlled with topical prescription therapies.

CONTRAINDICATION: NEMLUVIO is contraindicated in patients with known hypersensitivity to nemolizumab-ilto or to any of the excipients in NEMLUVIO.

WARNINGS AND PRECAUTIONS:

Hypersensitivity reactions have been reported with NEMLUVIO use. If clinically significant hypersensitivity reaction occurs, immediately institute appropriate therapy, and discontinue NEMLUVIO. Avoid use of live vaccines during treatment with NEMLUVIO.

ADVERSE REACTIONS:

Most common adverse reactions (incidence $\geq 1\%$) are headache (including migraine), arthralgia, urticaria, and myalgia.

USE IN SPECIFIC POPULATIONS:

Pregnancy: There are no adequate and well-controlled studies on NEMLUVIO in pregnant women. The limited available information on NEMLUVIO use during pregnancy is not sufficient to inform a drug-associated risk of major birth defects or miscarriage in humans. Human IgG antibodies are known to cross the placental barrier; therefore, NEMLUVIO may be transmitted from the mother to the developing fetus.

Lactation: There are no data on the presence or transfer of NEMLUVIO in human milk, the effects on the breastfed infant, or the effects on milk production. Human IgG is known to be present in human milk. The effects of local gastrointestinal and limited systemic exposure to NEMLUVIO on the breastfed infant are unknown. NEMLUVIO has not been administered to nursing/lactating women. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for NEMLUVIO and any potential adverse effects on the breastfed child from NEMLUVIO or from the underlying maternal condition.

Pediatric Use: The safety and effectiveness of NEMLUVIO has not been established in pediatric patients younger than 12 years of age for the treatment of moderate-to-severe atopic dermatitis.

Please see accompanying Prescribing Information or click here for full [Prescribing Information](#) including Patient Information.

Reference: 1. NEMLUVIO. Prescribing Information. Galderma Laboratories, L.P.

© 2024 Galderma Laboratories, L.P. All rights reserved. All trademarks are the property of their respective owners. US-NAD-2400037 (12/24)